OBJECTIVES The authors sought to evaluate 1-year clinical outcomes with the Lotus valve (Boston Scientific, Marlborough, Massachusetts) in a large international, multicenter prospective registry including patients eligible for transcatheter aortic valve replacement (TAVR) based on heart team consensus.
T ranscatheter aortic valve replacement (TAVR) is a safe and effective treatment for patients with symptomatic severe aortic stenosis at intermediate or high surgical risk (1) (2) (3) (4) (5) . With the expansion of TAVR eligibility to include lowerrisk patients, management of procedure-related complications is increasingly important, along with a focus on longer-term outcomes. the Lotus valve in patients at high risk for surgical valve replacement (8, 9) . The recent REPRISE III (11) . Approximately one-third of patients required a new pacemaker at 30 days.
Here, we report 1-year outcomes from the RESPOND study, the largest population to date treated with the Lotus valve in clinical practice.
Additionally, we report 30-day outcomes from an extension cohort of the RESPOND study treated with the next-generation Lotus valve with Depth Guard. (6, 7, 9) . ( Figure 1A) . The cumulative all-cause mortality rate at 1 year was 11.7% ( Figure 2 , Table 2 ). In a post hoc subgroup analysis, patients with a higher left At baseline, 62.4% of patients were NYHA functional class III; an additional 7.1% were class IV ( Figure 6A ).
METHODS
The significant improvement in NYHA functional class at 30 days post-procedure was maintained at 1
year, with nearly 90% of surviving patients classified as NYHA functional class I or II; 79% and 31% of patients had improved at least 1 or 2 classes, respectively, relative to baseline (p < 0.001 for both).
Health-related quality of life, as measured by the selfrated EuroQoL EQ-5D questionnaire, was significantly improved from baseline at 30 days post-procedure, with improvements sustained through 1 year ( Table 3 ). The change in patients' self-reported score on the Visual Analog Scale was representative of a clinically meaningful change in overall quality of life (13) .
RESPOND EXTENSION COHORT. The RESPOND Extension cohort enrolled 50 patients between June 2016 and October 2016 ( Figure 1B) ; baseline patient and echocardiographic characteristics are shown in Additional safety outcomes for the RESPOND Extension cohort are shown in Table 5 .
Echocardiographic data at hospital discharge were available for 37 of 50 patients (74%). Aortic valve area (effective orifice area) was 0.7 AE 0.2 cm 2 at baseline and 1.7 AE 0.3 cm 2 at discharge (p < 0.001). Mean aortic valve gradient declined from 39.8 AE 13.7 mm Hg at baseline, to 11.8 AE 4.4 mm Hg at discharge (p < 0.001).
There were no patients in the Extension cohort with moderate or severe PVL; 86.5% of patients exhibited no or trace PVL, and 13.5% of patients had mild PVL ( Figure 5B) . At baseline, 51.0% of patients were NYHA functional class III, and 2.0% were class IV ( Figure 6B) . At 30 days post-procedure, over 95% of surviving patients were classified as NYHA functional class I or II, with 72.3% and 27.7% of patients having improved at least 1 or 2 classes, respectively (p < 0.001 for both). All-cause mortality 0 (0) Cardiovascular mortality 0 (0) All stroke 3 (6) Disabling stroke 10 ( Abbreviations as in Table 2 . Table 1 .
Abbreviations as in
Van Mieghem et al. STUDY LIMITATIONS. The RESPOND study is not a randomized study, and thus lacks a direct comparator. Additionally, echocardiographic follow-up at 1
year was available for only 62.6% of the as-treated population (551 of 880 surviving patients). The rate of echo follow-up in the RESPOND study is similar to that seen in contemporary TAVR studies/registries at 1 year (PARTNER 2A 72.0% [4] ; SOURCE 3 60.4% [14] ;
ADVANCE 60.0% [15] ). The RESPOND protocol reflected standard practice, and 1-year echocardiographic follow-up is not the standard of practice at all institutions; it is often difficult to get patients to return to the study site, particularly when they are participating in a post-market registry. Because longer-term echocardiographic data would aid in understanding the impact of PVL on clinical outcomes, the RESPOND study will continue to collect such data at those sites for which annual echocardiographic follow-up is the standard of care.
CONCLUSIONS
The RESPOND post-market study is unique in that, to our knowledge, it is the only prospective TAVR registry presenting data with independent clinical event adjudication and echocardiographic core laboratory assessment at 1 year. One-year outcomes from the RESPOND study confirm the sustained safety and ef- The RESPOND Study 1-Year Outcomes
